deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01609790

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma

Sponsor: NRG Oncology

Conditions Giant Cell Glioblastoma Glioblastoma Gliosarcoma Oligodendroglioma Recurrent Brain Neoplasm Recurrent Glioblastoma
Interventions Bevacizumab Laboratory Biomarker Analysis Pharmacological Study Placebo Administration Trebananib
Updated 31 times since 2017 Last updated: Jun 28, 2022 Started: Jun 4, 2012 Primary completion: Oct 2, 2015 Completion: May 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01609790, this PHASE2 trial focuses on Giant Cell Glioblastoma and Glioblastoma and remains completed. Sponsored by NRG Oncology, it has been updated 31 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Dec 2020 · 6 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

31 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 26 earlier versions

  1. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  8. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  13. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  14. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  15. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  16. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  17. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  18. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  19. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  20. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  21. Jun 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  22. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  23. Sep 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

  24. May 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  25. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  26. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , American Fork, United States , Anchorage, United States , Anderson, United States , Ann Arbor, United States , Antigo, United States , Asheville, United States , Atlanta, United States , Auburn, United States and 163 more locations